For decades, artificial sweeteners have lived under the shadow of controversy. They have been accused of confusing the body, harming the gut, and even encouraging overeating. Headlines and social media have fueled this narrative, often without the depth of evidence…
In a major step forward for people with type 2 diabetes, MedPage Today reports that the FDA has approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk adults — whether or not they’ve had such an event already. That means…
For months, the national conversation around GLP-1 drugs has focused on one question: can anyone afford to stay on them long enough to see results? It’s a valid concern. Medications like semaglutide and tirzepatide have transformed obesity care, but their…
A new study has given researchers a clearer picture of why popular GLP-1 weight-loss drugs like Ozempic and Zepbound appear to curb alcohol cravings. Published in Scientific Reports, the pilot study found that these medications may slow the speed at which…
For years, Body Mass Index (BMI) has been treated as the universal measure of health. A simple calculation that places people into neat categories of “normal,” “overweight,” or “obese.” But a new study published in JAMA Network Open suggests that this…
GLP-1 medications have quickly become a cornerstone of modern weight management, reshaping how patients and clinicians approach obesity, diabetes, and metabolic health. These drugs—marketed under names like Ozempic, Wegovy, Zepbound, and Mounjaro—work by mimicking natural hormones that regulate appetite and blood…
When Novo Nordisk announced that Ozempic and Wegovy would now be available at Costco pharmacies for $499 per month, it marked an important step in expanding access to one of the most significant medical breakthroughs in modern weight management. The move means that people without…
There’s a phrase we’ve all heard before: “I’ll start after the holidays.” It sounds reasonable. After all, the next few months are packed with parties, travel, and never-ending to-do lists. But here’s the truth: if you wait until January to focus…
Let’s skip the magic-pill fantasy. The new GLP-1s work; the STEP and SURMOUNT trials bragged about 15% to 21% average weight loss. Then the real world showed up with missed refills, half-titrated doses, and stomachs that revolt. A large multidisciplinary…
Step on a traditional scale, and what do you see? A single number. That number, whether it is higher, lower, or exactly the same as yesterday, can dictate your mood, your motivation, and even how you see yourself. But here’s…